



enterprise europe

Boletín de Oportunidades de Cooperación:

Biotecnología y Salud

Boletín nº 146

Septiembre 2016



Agencia Andaluza del Conocimiento
CONSEJERÍA DE ECONOMÍA Y CONOCIMIENTO



Índice

Referencia	Título	Tipo Perfil
RDES20160708001	H2020-SC1-PM-15-2017. SME and R&D centre experts in Alzheimer are being sought	Research & Development Request
RDDE20160815001	H2020: Postdoc in biology/biomedicine for MSCA "Society and Enterprise Panel" sought	Research & Development Request
TOCH20160708001	Hand-held ultrasound imaging of breast for tumour screening	Technology Offer
TOSK20160719002	A small Slovak company has developed an automatic external public defibrillator and is looking for licensees	Technology Offer
TOUK20160711001	Novel multiplex polymerase chain reaction (PCR) detection methods for infectious disease testing and cancer mutation detection	Technology Offer
TOAR20160713001	Molecular Sensing Method Based on Luminescence Modulation through Specific Nanoparticle Heating	Technology Offer
TOHU20160713001	Re- and de novo sequencing of microbial genomes for the personalized medicine	Technology Offer
TRUK20160607001	UK SME Seeking clinical research partners (heart failure, fluid overload, oedema)	Technology Request

Research & Development Request

H2020-SC1-PM-15-2017. SME and R&D centre experts in Alzheimer are being sought

Summary

A Spanish university is willing to submit a H2020-SC1-PM-15-2017 (Personalised coaching for well-being and care of people as they age) project proposal. The aim of the project is to improve the cognitive response and the communicative interaction in Alzheimer patients with their caregivers. SME and R&D centre are being sought to fulfil the consortium.

Creation Date	13 July 2016
Last Update	19 July 2016
Expiration Date	19 July 2017
Reference	RDES20160708001
Profile link	http://een.ec.europa.eu/tools/services/PRO/Profile/Detail/d3affa42-25c9-4487-8188-c1d820bc22a5

Details

Description

The main objective of this project is to analyze whether several prosodic strategies can improve the cognitive response and the communicative interaction between the Alzheimer's disease patients (AD) and their caregivers. The study aims at assessing how a variety of instructions delivered with different prosodic variations is cognitively processed by patients to enhance their attention, motivation, comprehension, and emotional mood.

Some communication guidelines have been recommended to improve the interaction between Alzheimer patients and their caregivers. Prosody (the way to speak using intonation, stress and speech rate) has been only recently studied as a new way to diagnose the disease or with the aim at recognizing emotions. However, there are not studies for analyzing whether Alzheimer patients are sensitive to prosody variations and, if so, whether the ways in which caregivers speak to them may improve their communicative interaction. Therefore, the goal is to study if these prosody strategies can improve attention, motivation, comprehension and emotional mood of these patients to ultimately enhance their quality of life.

To do this, a combination of qualitative and quantitative methods will be applied. The qualitative methods will assess the caregivers needs and impressions about their relationship with patients. The quantitative ones will measure the cognitive response of AD patients. First, with the psychophysiological response, the attention, activation and emotional of the participants will be analyzed. Secondly, a videogame will measure motivation and comprehension based on different tasks. If the AD patients respond to prosody, the results of this study may serve to implement an Alzheimer's Caregiver Training.

An experienced university in EU projects with expertise in the field of communication and psychology will be the leader of the project and is looking for SME and R&D centres to complete

the consortium and carry out the project.

H2020-SC1-PM-15-2017: Personalised coaching for well-being and care of people as they age

Call deadline 31/01/2017

Deadline for Eols: 30/12/2016

Keywords

Technology

06001012	Medical Research
06001013	Medical Technology / Biomedical Engineering
06001014	Neurology, Brain Research

Market

05007004	Monitoring equipment
05007006	Computer-aided diagnosis and therapy

NACE

Q.86.1.0	Hospital activities
Q.86.9.0	Other human health activities
Q.87.2.0	Residential care activities for mental retardation, mental health and substance abuse
Q.87.3.0	Residential care activities for the elderly and disabled

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person

María Fernández Santa Cruz Campos

Phone Number

+34 955 00 74 75

Email

maria.fernandezsantacruz@juntadeandalucia.es

Open for EOI : **Yes**

Dissemination

Send to Sector Group

Healthcare

Client

Type and Size of Organisation Behind the Profile

University

Year Established

0

Already Engaged in Trans-National Cooperation

Yes

Experience Comments

An experienced university in EU projects with expertise in the field of communication and psychology

Languages Spoken

English
Spanish

Client Country

Spain

Partner Sought

Type and Role of Partner Sought

SME and research centre are being sought within the Alzheimer, psychology, neuroscience, linguistics and technology field of expertise.

The tasks to be performed should be:

- Patient recruitment
- Alzheimer evaluation
- Run the experiment (cross-cultural)
- Technical implement of the video game to evaluate the disease
- Training in prosody skills

Looking for non-Spanish partners.

Type and Size of Partner Sought

SME 11-50, University, R&D Institution, SME <10, SME 51-250

Type of Partnership Considered

Research cooperation agreement

Research & Development Request

H2020: Postdoc in biology/biomedicine for MSCA "Society and Enterprise Panel" sought

Summary

A German company, leading in the field of medical technology, is looking for postdoctoral researchers to work on a research and innovation project. The project should have a duration of maximum 24 months and will be funded through the "Society and Enterprise Panel" of Marie Skłodowska-Curie actions. Applicants must hold MD/PhD or a PhD degree in biology, biomedicine or similar.

Creation Date	15 August 2016
Last Update	25 August 2016
Expiration Date	25 August 2017
Reference	RDDE20160815001
Profile link	http://een.ec.europa.eu/tools/services/PRO/Profile/Detail/0062f16d-d221-4df7-a8b6-a48d59e63b81

Details

Description

The company is one of the world's leading medical technology companies. It offers a diverse array of innovative medical technologies, including reconstructive, medical and surgical, and neurotechnology and spine products to help people lead more active and more satisfying lives. Their products and services are available in over 100 countries.

The company is looking for postdoctoral researchers to scientifically work on a specific research and innovation project with a maximum duration of 24 months (2 years) at the earliest possible date. The research project will be funded by the European Union's Marie Skłodowska-Curie actions. As part of the European Union's Horizon 2020 Framework Programme to foster Research and Innovation within the European Union, the Marie Skłodowska-Curie actions (MSCA) provide grants for highly experienced researchers and encourage transnational, intersectoral and interdisciplinary mobility. The MSCA enable research-focused organizations (universities, research centers, and companies) to host talented foreign researchers and to create strategic partnerships with leading institutions worldwide. The call deadline is 14th September 2016 and the deadline for the EoI is 5th September. The topic and the focus of the research project will be defined in cooperation with the researcher and their qualifications and interests.

Keywords

Technology

06001013

Medical Technology / Biomedical Engineering

06001017	Surgery
06001020	Physiotherapy, Orthopaedic Technology
06001023	Medical Furniture

Market

05004003	Laboratory equipment
05004004	Medical instruments
05004005	Diagnostic equipment
05004006	Surgical instrumentation and equipment

NACE

Q.86.2.2	Specialist medical practice activities
Q.86.9.0	Other human health activities

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person

María Fernández Santa Cruz Campos

Phone Number

+34 955 00 74 75

Email

maria.fernandezsantacruz@juntadeandalucia.es

Open for EOI : **Yes**

Dissemination

Send to Sector Group

Healthcare

Client

Type and Size of Organisation Behind the Profile

Industry >500 MNE

Year Established

0

Already Engaged in Trans-National Cooperation

Yes

Languages Spoken

English
German

Client Country

Germany

Partner Sought

Type and Role of Partner Sought

Applicants must hold MD/PhD or a PhD degree in biology, biomedicine or similar. Scientists with a strong background in biomechanics, musculoskeletal regeneration, or material sciences are welcome.

A solid publication record should be provided. The ability to critically assess cutting edge publications related to research and to clinical results in the field is required. Excellent knowledge of the English language and experience in writing manuscripts and bids will also be necessary. Knowledge of other languages (e.g. German) is beneficial but not compulsory.

The company expects a written proposal of the researcher's research and innovation project (maximum length: 10 pages, excluding annexes) in English by the time of the formal application for the MSCA funding scheme. A Career Development Plan will be established jointly by the supervisor(s) and the researcher (comprised of the researcher's training and career needs, including training on transferable skills, planning for publications and participation in conferences). The formal application will be made jointly by the researcher and the company. A meaningful letter of motivation as well as a current CV of the applicant (maximum: 5 pages) are expected for a first evaluation.

The postdoctoral researchers will scientifically work on a specific research and innovation project with a maximum duration of 24 months (2 years).

Type of Partnership Considered

Research cooperation agreement

Technology Offer

Hand-held ultrasound imaging of breast for tumour screening.

Summary

A Swiss university of technology offers a screening method for breast cancer. The method is based on ultrasound. Unlike a mammogram the ultrasound scan is radiation-free and painless and provides higher sensitivity for tumours in dense breasts. The newly developed ultrasound probe head is compatible with most commercial ultrasound scanners used by doctors. A licensing partner who develops the prototype to an industrial product and introduces the new scanner to the market is sought.

Creation Date	08 July 2016
Last Update	21 July 2016
Expiration Date	11 July 2017
Reference	TOCH20160708001
Profile link	http://een.ec.europa.eu/tools/services/PRO/Profile/Detail/99ce9066-5d8b-4630-bab0-3aba80ac5a77

Details

Description

Background

X-ray mammography is the current method for breast cancer screening. However, a mammogram is rather painful as it requires the compression of the breast. Also, a potentially harmful radiation dose is administered during the scan and the sensitivity for dense breasts is limited.

Detailed Description

The ultrasound screening method proposed by the Swiss university of technology is a time-of-flight method. The probe head is at the same time an emitter and a sensor. The head emits an ultrasound wave which travels through the tissue. A hand-held reflector is positioned on the other side of the tissue, so that the sound waves are back-reflected to the probe head (see picture). The time between emission of the ultrasound wave and detection of its echo is recorded.

The propagation speed of the wave through the tissue depends on the stiffness of the tissue. The stiffer the tissue the faster the propagation speed of the wave. Cancer tissue is stiffer than glandular tissue or other breast structures (skin, cysts). Thus, a strong contrast for cancerous tissue is obtained in the resulting image by recording variations in the travel times of the ultrasound waves. The ultrasound probe head was developed with an imaging processing program. The computing algorithm for the image processing is also covered by the patent.

Application

The technique can in general be applied to the screening of protruding/external tissues such as breast, testicles, skin, cartilage and the extremities. It is a non-destructive imaging technique.

Partnership

A prototype was built and is currently tested on patients in a clinical facility. In a next step the university researchers will refine the technology. For the development of the prototype to an industrial product and the commercialisation a licensing partner in the field of medical technology is sought.

Advantages and Innovations

- The ultrasound screening technology outperforms X-ray mammography in several scenarios.
- It's a low-cost add-on to conventional ultrasound systems.
- It minimizes patient discomfort.
- It's a simple operation for the sonographer, similar to conventional ultrasound

Stage of Development

Prototype available for demonstration

IPR Status

Granted patent or patent application essential

Comment Regarding IPR status

European Patent application (August 2015)

Profile Origin

Private (in-house) research

Keywords

Technology

01003012	Imaging, Image Processing, Pattern Recognition
01004001	Applications for Health
06001003	Cytology, Cancerology, Oncology
06001005	Diagnostics, Diagnosis
09001001	Acoustic Technology related to measurements

Market

02007012	Medical/health software
05002003	Ultrasound imaging
05004005	Diagnostic equipment
05005014	Oncology
05007006	Computer-aided diagnosis and therapy

NACE

Q.86.9.0	Other human health activities
----------	-------------------------------

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person

María Fernández Santa Cruz Campos

Phone Number

+34 955 00 74 75

Email

maria.fernandezsantacruz@juntadeandalucia.es

Open for EOI : **Yes**

Dissemination

Send to Sector Group

Healthcare

Client

Type and Size of Organisation Behind the Profile

University

Year Established

0

Already Engaged in Trans-National Cooperation

Yes

Languages Spoken

English

German

Client Country

Switzerland

Partner Sought

Type and Role of Partner Sought

The specific area of activity of the partner:

- medicinal technology
- manufacturer of ultrasound scanners with R&D department

The tasks to be performed by the partner sought:

- develop the prototype to an industrial product for the cancer screening market
- introduce new technology to market

Type and Size of Partner Sought


SME 11-50, SME <10, >500 MNE, 251-500, SME 51-250, >500

Type of Partnership Considered

License agreement

Attachments

Ultrasound.png



Technology Offer

A small Slovak company has developed an automatic external public defibrillator and is looking for licensees

Summary

A small company from the western part of Slovakia active in the field of medical devices is offering a defibrillation technology suitable for professionals and non-professionals. The charger enables the device to work even if the battery is weak. It is equipped with a large LCD screen which enables you to see and read a recorded ECG (electrocardiogram) line. Partners are sought to cooperate via license agreement.

Creation Date	19 July 2016
Last Update	19 July 2016
Expiration Date	19 July 2017
Reference	TOSK20160719002
Profile link	http://een.ec.europa.eu/tools/services/PRO/Profile/Detail/645412fd-60f5-4db0-942b-83b51a82e092

Details

Description

The technology was developed for non-professional's to save peoples lives when CPR (cardiopulmonary resuscitation) is not enough. It uses the same advanced technology used by medical professionals, including the latest biphasic technology, on the other hand operating it is as easy as using a fire extinguisher. Just one button activates a cycle of steps needed to help save someone's life. The developers have thought of everything, even the failure to remember to check the battery. Most devices have batteries that need to be recharged and in the event that the battery goes dead the device does not work. The charger enables the device to work even if the battery is weak. It is still fully operative.

It is equipped with large LCD screen which enables anybody to see and read a recorded ECG line. The battery capacity enables 400 discharges. Switching from the automatic mode to the manual mode is fast and easy. There is a great advantage in use for trained professionals; doctors, nurses, fire fighters. It also uses the latest biphasic technology, cprMAX technology.

The company is looking for partners to cooperate via license agreement. This type of cooperation was selected, because it fits today's need of this company in a best suitable way.

Advantages and Innovations

Slovak company is top supplier of external defibrillation technology around the world.

It uses the same advanced technology used by medical professionals.

The charger enables the device to work even if the battery is weak.

It is equipped with large LCD screen which enables you to see and read a recorded ECG line.

Stage of Development

Already on the market

IPR Status

Secret Know-how

Profile Origin

Private (in-house) research

Keywords

Technology

06001007	Emergency medicine
06001013	Medical Technology / Biomedical Engineering

Market

05001001	Diagnostic services
05003001	Therapeutic services
05004002	Rescue and emergency equipment
05004004	Medical instruments

NACE

Q.86.1.0	Hospital activities
Q.86.9.0	Other human health activities
Q.87.9.0	Other residential care activities

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person

María Fernández Santa Cruz Campos

Phone Number

+34 955 00 74 75

Email

maria.fernandezsantacruz@juntadeandalucia.es

Open for EOI : **Yes**

Client

Type and Size of Organisation Behind the Profile

Industry SME 11-49

Year Established

0

Already Engaged in Trans-National Cooperation

No.

Languages Spoken

English
Slovak

Client Country

Slovakia

Partner Sought

Type and Role of Partner Sought

- Type of partner sought: Medical centres, rescue services.
- Specific area of activity of the partner: rescue and medicine sector - doctors, nurses, fire fighters.
- Task to be performed by the partner sought: development of further applications of this technology via license agreement.

Type and Size of Partner Sought

SME 11-50, Inventor, R&D Institution, SME <10, >500 MNE, 251-500, SME 51-250, >500

Type of Partnership Considered

License agreement

Technology Offer

Novel multiplex polymerase chain reaction (PCR) detection methods for infectious disease testing and cancer mutation detection

Summary

A UK SME has developed a novel detection method which has multiple possible applications in medical diagnostics. The method allows the detection of multiple targets in a single analysis using current standard instrumentation, enabling multiplex detection of more targets in a single closed-tube reaction than currently possible. The company seeks companies/institutions for licensing & marketing opportunities, or for co-development via technical or commercial agreement with technical assistance.

Creation Date	11 July 2016
Last Update	14 July 2016
Expiration Date	14 July 2017
Reference	TOUK20160711001
Profile link	http://een.ec.europa.eu/tools/services/PRO/Profile/Detail/2a4d571e-6de4-431d-88ee-25cbfd7d9b99

Details

Description

The company has developed several patented technologies in the fields of multiplex real-time PCR and Next Generation Sequencing, and has CE IVD (In-Vitro Diagnostic Medical Devices) products in the market.

- MPA (Multiplex Probe Amplification) is a platform real-time PCR-based technology allowing detection and genotyping of up to 20 different targets in a single closed-tube reaction, significantly increasing throughput capabilities. Papilloplex HR-HPV Genotyping Assay is a CE IVD marked product for detection, differentiation and quantitation of all 14 high-risk HPV types in a single analysis.
- MMD-PCR (Multiplex Mutation Detection) is technology for cancer gene mutation detection. It has features: detection of multiple mutations in a single analysis; reduced reaction tubes to preserve clinical material, save reagents and allow high-throughput; sensitive simple real-time PCR reaction; internal endogenous control to further reduce the number of reactions required.
- TBD-seq (Tagged BiDirectional Sequencing) is a sensitive next generation sequencing technology, which is well suited to detecting ultra-rare cancer gene mutations in the blood.

They are seeking companies or research centres to co-develop the products via commercial agreements with technical assistance or technical cooperation agreements, or to license the

technologies.

Advantages and Innovations

Multiplex real-time PCR offers numerous advantages, including time savings, elimination of contamination risk, reduced reagent costs, increased throughput, conservation of precious sample material and reliable results. However, current probe-based methods allow detection of only one target sequence per fluorescence channel. The multiplex fluorescent PCR is therefore limited by the availability of fluorescence dyes and channels; up to five or six targets, depending on particular PCR machines, can be detected simultaneously in the current platforms.

This technology inherits all the benefits of the traditional TaqMan-based real-time PCR at the same time offering several advantages due to its increased multiplexing capabilities:

- increased speed of analysis
- reduced quantity of starting material
- reduced risk of contamination
- reduced overall costs as more targets are analyzed with the same amount of reagents

Stage of Development

Already on the market

IPR Status

Patents granted

Comment Regarding IPR status

The patents have been granted in Europe, US, China, pending in Japan, Canada, Australia

Profile Origin

Other

Keywords

Technology

06001005	Diagnostics, Diagnosis
06002002	Cellular and Molecular Biology
06002007	In vitro Testing, Trials

Market

04001003	Medical genetic engineering applications
05001001	Diagnostic services
05001002	In-vitro diagnostics
05004005	Diagnostic equipment

NACE

M.72.1.1	Research and experimental development on biotechnology
Q.86.2.2	Specialist medical practice activities
Q.86.9.0	Other human health activities

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person

María Fernández Santa Cruz Campos

Phone Number

+34 955 00 74 75

Email

maria.fernandezsantacruz@juntadeandalucia.es

Open for EOI : **Yes**

Dissemination

Send to Sector Group

Bio Chem Tech

Client

Type and Size of Organisation Behind the Profile

Industry SME <= 10

Year Established

0

Already Engaged in Trans-National Cooperation

Yes

Languages Spoken

English
Chinese

Client Country

United Kingdom

Partner Sought

Type and Role of Partner Sought

- Type of partner sought: companies or research institutions
- Specific area of activity of the partner: development of novel diagnostic applications
- Task to be performed by the partner sought: co-development of technology to new applications via commercial agreement with technical assistance, or technical cooperation agreements or licensing of existing technology

Type of Partnership Considered

- License agreement
- Commercial agreement with technical assistance
- Technical cooperation agreement

Technology Offer

Molecular Sensing Method Based on Luminescence Modulation through Specific Nanoparticle Heating

Summary

A research institution from Argentina, dedicated to the promotion of science and technology in this country and abroad, have developed a molecular sensing method based on luminescence modulation through specific nanoparticle heating in homogeneous phase reaction. This institution is looking for companies acquiring this technology for its development into an analytical system for its exploitation. Types of cooperation: licensing, commercial agreement with technical assistance.

Creation Date	13 July 2016
Last Update	25 July 2016
Expiration Date	25 July 2017
Reference	TOAR20160713001
Profile link	http://een.ec.europa.eu/tools/services/PRO/Profile/Detail/03e54a52-a44f-45bd-a4d8-4c23f0b07367

Details

Description

This invention represents a molecular sensing method (for detecting and quantifying molecular interactions) based on luminescence modulation through specific nanoparticle heating. The method takes advantage of the local, specific and nanometric heating around nanoparticles to detect the effect of temperature on luminescent species. The mechanism can be applied to the detection of any molecule of interest (for example, protein) having at least one recognition entity (antibodies for instance).

Applications:

- Detecting the presence of or quantifying the concentration of a relevant molecule at biological, medical, pharmacological or analytical level.
- Obtaining information about the biorecognition reaction kinetics.

Advantages and Innovations

- Sub- nanomolar sensitivity in the detection of analytes.
- Possible to establish an homogeneous (1 phase) or inhomogeneous (several phases or including segregation steps) system.
- Sensitivity and working concentration range can be adapted to the needs by modifying the concentrations of nanoparticles and luminescent species.
- Allows sensing different analytes or different concentration ranges simultaneously.

Stage of Development

Under development/lab tested

Comments Regarding Stage of Development

Proof of concept was demonstrated by quantification of streptavidin. For this model, cylindrical gold nano-rods and AlexaFluor546 were used.

IPR Status

Patent(s) applied for but not yet granted

Comment Regarding IPR status

PCT application

Profile Origin

Private (in-house) research

Keywords

Technology

05001001	Analytical Chemistry
05005	Micro- and Nanotechnology
06001005	Diagnostics, Diagnosis
06002001	Biochemistry / Biophysics
09001002	Analyses / Test Facilities and Methods

Market

04005	Biochemistry / Biophysics
04017	Micro- and Nanotechnology related to Biological sciences
05001002	In-vitro diagnostics

NACE

M.71.2.0	Technical testing and analysis
M.72.1.9	Other research and experimental development on natural sciences and engineering
Q.86.9.0	Other human health activities

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person

María Fernández Santa Cruz Campos

Phone Number

+34 955 00 74 75

Email

maria.fernandezsantacruz@juntadeandalucia.es

Open for EOI : **Yes**

Dissemination

Send to Sector Group
Bio Chem Tech

Client

Type and Size of Organisation Behind the Profile

Other

Year Established

0

Already Engaged in Trans-National Cooperation

No.

Languages Spoken

English
Spanish

Client Country

Argentina

Partner Sought

Type and Role of Partner Sought

CONICET is currently looking for licensed partners to spread the developed technology to new countries and regions.

First and foremost, it should be an innovator company in the field of analytical chemistry applied to health (diagnosis), biological sciences, environmental sciences, for example, with strong committed to improve people's quality of life.

Type and Size of Partner Sought

SME 11-50, University, Inventor, R&D Institution, SME <10,>500 MNE, 251-500, SME 51-250, >500

Type of Partnership Considered

License agreement
Commercial agreement with technical assistance
Research cooperation agreement

Technology Offer

Re- and de novo sequencing of microbial genomes for the personalized medicine

Summary

The research group of a Hungarian university applies the new generation sequencing techniques in the field of molecular microbiology. They created a fast, automatable and scalable method that helps make it possible to fully understand the DNA and RNA genomes. The research group seeks international partners from the field of genomics, population genomics and biotechnology to utilize the findings of its research and to use its services in the form of service agreement and research cooperation.

Creation Date	13 July 2016
Last Update	22 July 2016
Expiration Date	22 July 2017
Reference	TOHU20160713001
Profile link	http://een.ec.europa.eu/tools/services/PRO/Profile/Detail/868d1c75-ebda-4026-9818-fd8f3c41f3f5

Details

Description

The research group of the Hungarian university owns the necessary knowledge and instruments to the technology which can be used multifaceted.

Methods that are able to sequence lot of samples simultaneously belong to the new generation sequencing, i.e. they are high-throughput (HTP) methods. Highly developed robotics and computer capacity are required for their use.

With the introduction of the new generation methods, the efficiency of the DNA based studies increased explosively, and their specific cost decreased. With a new generation sequencer it is possible to sequence even the human genome in a few weeks or even in a few hours. Primarily they are applied in the field of functional and environmental genomics (metagenomics), and in the field of transcriptome studies. These methods are suitable not only for the sequencing of DNA, but also for sequencing of mRNA, small RNAs and the so called CHIPseq sequencing as well. From these results it can be directly concluded to the expression status of a cell or a material to be studied, and to the regulatory regions of the DNA.

Currently the DNA sequencing becomes the most dominant tool of the molecular biology.

The de novo sequencing is used if the genetic material of the given organism is read for the first time, therefore no reference sequence is available. At the same time its methods are usable in case of and search for larger scale realignments (e.g. mutations of tumor cells).

The full DNA file (which is amplified non-specifically) is fragmented into a size which is suitable for the chosen sequencing technology. Matching the sequence fragments formed during the reading is a very complex task, great coverage is required to organise the reads even for

chromosomes. For the de novo matching of the 3 billion base pair of the human DNA, cca. 100 million reads are necessary (depending on the technology). The genomes of the less difficult organisms are smaller by orders of magnitude (e.g. the genomes of the bacteria or viruses), so they can be fully matched even in one go.

Equipment used:

Ion Torrent semiconductor system

With the three-dimensional separation of each sample, simultaneous testing of more samples becomes possible.

The other equipment usually applied for the similar purpose use fluorescent paints and cameras for the detection of DNA elements. Contrast to them, the chip applied in Ion Torrent is able to detect those hydrogen ions, which are formed when a new element is added to the DNA strand. Recording the sequence in the given sample takes less than 1-2 hours, whereas in case of the much larger equipment the processing requires several days. The device encrypts the DNA string of letters directly via a semiconductor chip which measures the change in voltage instead of the light.

Available tests:

- Targeted DNA sequencing
- De novo microbial sequencing
- CHIP sequencing
- Copy number analysis
- Bacterial typing
- SNP validation
- Small RNA sequencing
- Metagenomics
- Genotyping by sequencing

Areas of use:

- Judicature, forensic science - determination of identity
- Identification of genetical risk factors, predispositions to diseases - the possibility of personalised medicine, since it makes possible for the patient to choose the most efficient therapy by knowing his/her DNA
- Detection of viruses, bacteria - identification of the source of infections
- Transplantation genetics - stem cell research
- Prenatal tests
- Study of known genes - primarily the diagnostic of monogenic diseases and to facilitate the choice of the appropriate treatment
- Personalized diagnostics and choice of medicinal products
- Cancer research - simultaneous determination of different genetical lesions
- Population genomics.

The Hungarian research group seeks partners active in the field of conventional and molecular microbiology, genomics, biotechnology and cytogenetics to sign a service and/or research agreement.

Advantages and Innovations

- Simultaneous sequencing of millions of base pairs (bp)
- Compared to the previous sequencing techniques, the process time of the tests are shorter by orders of magnitude.
- Cost effective
- Good ability of automatization
- No electrophoretic separation
- Multiplexible
- Possibility of simultaneous sequencing of targeted, disease specific genes

- Increased sensitivity
- High scalability

Stage of Development

Already on the market

IPR Status

Secret Know-how

Profile Origin

National or Regional R&D programme

Keywords

Technology

06001009	Gene - DNA Therapy
06002002	Cellular and Molecular Biology
06002005	Genetic Engineering
06002010	Toxicology
06003001	Bioinformatics

Market

04001001	Agricultural genetic engineering applications
04001002	Industrial genetic engineering applications
04001003	Medical genetic engineering applications
05001001	Diagnostic services

NACE

C.21.1.0	Manufacture of basic pharmaceutical products
C.21.2.0	Manufacture of pharmaceutical preparations
M.74.9.0	Other professional, scientific and technical activities n.e.c.
Q.86.9.0	Other human health activities

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person

María Fernández Santa Cruz Campos

Phone Number

+34 955 00 74 75

Email

maria.fernandezsantacruz@juntadeandalucia.es

Open for EOI : **Yes**

Dissemination

Send to Sector Group

Healthcare

Client

Type and Size of Organisation Behind the Profile

University

Year Established

0

Already Engaged in Trans-National Cooperation

Yes

Languages Spoken

English

Hungarian

Client Country

Hungary

Partner Sought

Type and Role of Partner Sought

Type of partner sought and its area of activity:

All those public or economic entities and/or universities - research institutes can be potential partners, who are active in the field of conventional and molecular microbiology, genomics, biotechnology and cytogenetics, and able to utilize the research group's technology and capacities.

Type of Partnership Considered

Services agreement

Research cooperation agreement

Technology Request

UK SME Seeking clinical research partners (heart failure, fluid overload, oedema)

Summary

A UK-based SME develops a novel approach for management of fluid overload unresponsive to diuretic therapy. Initial proof-of-concept studies have demonstrated the technology feasibility. The SME is now looking to support further research to evaluate the scalability and are looking to partner with hospitals, universities or research institutions within cardiovascular and/or chronic oedema domains to conduct further research as research cooperation, technical cooperation or services agreement.

Creation Date	07 June 2016
Last Update	13 July 2016
Expiration Date	13 July 2017
Reference	TRUK20160607001
Profile link	http://een.ec.europa.eu/tools/services/PRO/Profile/Detail/d329077d-67bd-44a6-b1c6-218d251bc903

Details

Description

Fluid overload and chronic oedema are significant and growing healthcare problems in Europe where 0.4% of the population, approximately 2 million people, are affected. Fluid overload causes breathlessness, oedema and increased risk of death and is a leading cause of hospital admissions. Current approaches use blood based fluid removal such as diuretics and when they fail, haemodialysis or peritoneal dialysis. As diuretics fail in 13-31% of cases, or can themselves cause complications such as acute kidney injury, alternative methods of treatment are needed.

A UK-based SME has developed a novel, minimally invasive intervention for fluid removal. This technology utilises micro-needles combined with a negative pressure therapy to access and remove excess interstitial fluid from the skin.

Initial proof-of-concept studies have demonstrated the technology feasibility.

The SME is now looking for research partners to further validate this technology. They are looking to partner with hospitals, universities or research institutions that have access to patients with congestive heart failure, kidney disease or other conditions resulting in fluid overload or chronic oedema that has proved resistant to treatment. The partner entity should have experience of running clinical research, ideally those using medical devices. It is envisaged that the partnership will take the form of a research cooperation, with funding opportunities under the Horizon 2020 programme being actively explored, a technical cooperation agreement or a services agreement.

Technical Specification or Expertise Sought

The SME is looking to partner with hospitals, universities or research institutions that have the experience and expertise necessary in order to further develop the SME's novel medical intervention. The partner should have access to patients with fluid overload or chronic oedema caused by congestive heart failure, kidney disease or other conditions and who have not responded to therapy. The partner should be able to help design and conduct the research as well as assist with report writing.

Keywords

Technology

06001011	Heart and blood circulation illnesses
06001013	Medical Technology / Biomedical Engineering

Market

05005010	Cardiology
05005012	Nephrology
05007001	Disposable products
05007007	Other medical/health related (not elsewhere classified)

NACE

M.72.1.1	Research and experimental development on biotechnology
Q.86.9.0	Other human health activities

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person

María Fernández Santa Cruz Campos

Phone Number

+34 955 00 74 75

Email

maria.fernandezsantacruz@juntadeandalucia.es

Open for EOI : **Yes**

Dissemination

Send to Sector Group

Healthcare

Client

Type and Size of Organisation Behind the Profile

Industry SME <= 10

Year Established

0

Already Engaged in Trans-National Cooperation

Yes

Languages Spoken

English
Polish

Client Country

United Kingdom

Partner Sought

Type and Role of Partner Sought

The SME is looking to partner with hospitals, universities or research institutions that have the experience and expertise necessary in order to further develop the SME's novel medical intervention. The partner should have access to patients with fluid overload or chronic oedema caused by congestive heart failure, kidney disease or other conditions and who have not responded to therapy. The partner should be able to help design and conduct the research as well as assist with report writing.

It is envisaged that the partnership will take the form of a research cooperation, with funding opportunities under the Horizon 2020 programme being actively explored, a technical cooperation agreement or a services agreement.

Type of Partnership Considered

Services agreement
Technical cooperation agreement
Research cooperation agreement